Literature DB >> 30483915

Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea.

Seo Yeon Baik1, Hyunah Kim2, So Jung Yang1, Tong Min Kim1, Seung-Hwan Lee3, Jae Hyoung Cho3, Hyunyong Lee4, Hyeon Woo Yim5, Kun-Ho Yoon1,3, Hun-Sung Kim6,7.   

Abstract

Few long-term follow-up studies have compared the changes in renal function according to the type of statin used in Korea. We compared the long-term effects of statin intensity and type on the changes in the glomerular filtration rate (GFR). We extracted data of patients who took statin for the first time. We analyzed whether or not different statins affect the changes in GFR at 3 months after baseline and 4 years after. We included 3678 patients and analyzed the changes in GFR. The GFR decreased by 3.2% ± 0.4% on average 4 years after the first statin prescription, indicating statistically significant deterioration (from 83.5 ± 0.4 mL/min/1.73 m2 to 79.9 0.4 mL/min/1.73 m2, P < 0.001). When comparing the GFR among different statins, significant differences were observed between atorvastatin and fluvastatin (-5.3% ± 0.7% vs. 1.2% ± 2.2%, P < 0.05) and between atorvastatin and simvastatin (-5.3% ± 0.7% vs. -0.7% ± 0.8%, P < 0.05). In pitavastatin (odds ratio [OR]= 0.64, 95% confidence interval [CI]= 0.46-0.87, P < 0.005) and simvastatin (OR = 0.69, 95% CI = 0.53-0.91, P < 0.008), the GFR rate that decreased by < 60 mL/min/1.73 m2 was significantly lower than that of atorvastatin. Regarding long-term statin intake, GFR changed with the type of statin. This work is the first in Korea to compare each statin in terms of changes in the GFR after the statin prescription.

Entities:  

Keywords:  HMG-CoA reductase inhibitor; chronic kidney disease; glomerular filtration rate; statin

Mesh:

Substances:

Year:  2018        PMID: 30483915     DOI: 10.1007/s11684-018-0661-9

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  40 in total

Review 1.  Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

Authors:  Vito M Campese; Mitra K Nadim; Murray Epstein
Journal:  J Am Soc Nephrol       Date:  2005-03       Impact factor: 10.121

2.  Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers.

Authors:  Tsung-Ming Lee; Mei-Shu Lin; Chang-Her Tsai; Nen-Chung Chang
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

3.  Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

Authors:  Michelle A Albert; Robert J Glynn; Francisco A H Fonseca; Alberto J Lorenzatti; Keith C Ferdinand; Jean G MacFadyen; Paul M Ridker
Journal:  Am Heart J       Date:  2011-06-12       Impact factor: 4.749

4.  Pravastatin and cardiovascular risk in moderate chronic kidney disease.

Authors:  Haruo Nakamura; Kyoichi Mizuno; Yasuo Ohashi; Tomowo Yoshida; Koichi Hirao; Yasufumi Uchida
Journal:  Atherosclerosis       Date:  2009-04-05       Impact factor: 5.162

5.  Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease.

Authors:  Gen Yasuda; Tadashi Kuji; Kyoko Hasegawa; Nariaki Ogawa; Gaku Shimura; Daisaku Ando; Satoshi Umemura
Journal:  Ren Fail       Date:  2004-07       Impact factor: 2.606

6.  Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Authors:  James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 8.237

7.  Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway.

Authors:  Satoru Sharyo; Naoko Yokota-Ikeda; Miyuki Mori; Kazuyoshi Kumagai; Kazuyuki Uchida; Katsuaki Ito; Melissa J Burne-Taney; Hamid Rabb; Masahiro Ikeda
Journal:  Kidney Int       Date:  2008-05-28       Impact factor: 10.612

8.  Postischemic acute renal failure is reduced by short-term statin treatment in a rat model.

Authors:  Faikah Gueler; Song Rong; Joon-Keun Park; Anette Fiebeler; Jan Menne; Marlies Elger; Dominik N Mueller; Franziska Hampich; Ralf Dechend; Uta Kunter; Friedrich C Luft; Hermann Haller
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

9.  Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005.

Authors:  Myung Ha Lee; Hyeon Chang Kim; Song Vogue Ahn; Nam Wook Hur; Dong Phil Choi; Chang Gyu Park; Il Suh
Journal:  Diabetes Metab J       Date:  2012-02-17       Impact factor: 5.376

10.  Age Is the Strongest Effector for the Relationship between Estimated Glomerular Filtration Rate and Coronary Artery Calcification in Apparently Healthy Korean Adults.

Authors:  Hyun Beom Chae; Shin Yeoung Lee; Nam Hee Kim; Ki Joong Han; Tae Hoon Lee; Choel Min Jang; Kyung Mo Yoo; Hae Jung Park; Min Kyung Lee; Won Seon Jeon; Se Eun Park; Heui-Soo Moon; Cheol-Young Park; Won-Young Lee; Ki-Won Oh; Sung-Woo Park; Eun-Jung Rhee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.